Articles On Kazia Therapeutics (ASX:KZA)

SYDNEY, Nov. 29, 2021 /PRNewswire/ – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to inform stakeholders that the GBM AGILE study in glioblastoma (NCT03970447) has opened a...

The Sydney-based company’s flagship drug, paxalisib, is a candidate in a multi-drug platform study designed to identify promising new therapies for glioblastoma.  

He’s baaack! Fresh from founding and listing immune-oncology play Chimeric, Paul Hopper can add Radiopharm Theranostics (ASX:RAD) to his boardroom rota after the nuclear medicine play listed on the ASX on Thursday – albeit limply. The count...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Highlights As per experts, the global cancer drug market is likely to accelerate in the upcoming years due to the widespread prevalence of cancer.  The increased focus of the healthcare sector on cancer research has been a critical fac...

SYDNEY, Nov. 16, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the appointment of John Friend, MD, as Chief Medical Officer. In this role,...

Dr Friend will be responsible for overseeing the development and commercialization of Kazia’s pipeline drug candidates, and collaborate with clinicians and scientists to advance the company’s research programs.

SYDNEY, Nov. 11, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that PNOC022 (NCT05009992), a multi-drug phase II study in DIPG and diffuse mi...

The ASX 200 Health Index (XHJ) is down by 1.0% at the time of writing, compared to the broader index which is down by 0.1%. Medical diagnostics company, Universal Biosensors (ASX:UBI), has entered into a collaboration agreement with Mayo Cl...

"There remains a desperate need for new treatment options in this disease, and we hope that paxalisib may be able to contribute to better outcomes for patients and their families,” says Kazia CEO.

Wall Street falls as US inflation hits 30-year high US stocks continued their slide overnight, as the latest data showed that consumer prices rose at a pace not seen since the early 1990s. Prices in the US jumped 0.9% in October, and 6.2% f...

ShareCafeDue Diligence Webinar – Kazia Therapeutics Presenter – James Garner CEO & Managing Director – Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company based in Sydney, Austral...

Kazia Therapeutics (KZA) enrols its first patient in the upcoming phase one clinical trial of EVT801 EVT801 is a small molecule inhibitor of VEGFR3 and works by hindering lymphangiogenesis, the formation of new lymphatic vessels around the...

The oncology-focused drug development company licensed the investigational cancer therapy, known as EVT801, from German biotech Evotec AG in April 2021.

The ASX 200 Health Index (XHJ) is up by 0.40% at the time of writing, compared to the broader index which is higher by 0.30%. Neurology specialist, Invex Therapeutics (ASX:IXC), soared 13% after announcing that it’s about to launch a Phase...

ASX-listed mobile health (mHealth) company Advanced Human Imaging (AHI) is moving forward with its planned dual-listing on the NASDAQ exchange Listing on the NASDAQ will place Advanced Human Imaging on one of the highest-quality and highes...

The Maxim Group has also put a 12-month target price of US$18 per ADS, saying the current stock price does not reflect its upside potential.

Edison has increased its valuation to A$375 million or A$2.83 per basic share from A$346 million or A$2.68 per basic share mainly due to rolling forward its Net Present Value (NPV).

SYDNEY, Oct. 6, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the LD Micro Main Event, to be he...

SYDNEY, Sept. 11, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the HC Wainwright 23rd Annua...

ShareCafeHidden Gems Webinar Recap – CYP, AT1, NSB & KZA Catch up on the full webinar with presentations from Cynata Therapeutics (ASX: CYP), Atomo Diagnostics (ASX: AT1), NeuroScientific (ASX: NSB) & Kazia Therapeutics (ASX: KZA)...

ShareCafeA high quality pipeline of cancer drugs James Garner – Managing Director & CEO – Kazia Therapeutics Limited is an innovative oncology-focused biotechnology company. Kazia is working to develop therapies across a range of on...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

“The second calendar quarter has been a busy and productive period for Kazia, as we bed down three substantial cross-border licensing deals,” says CEO.

Kazia says its future success will be measured by commercialisation milestones after the company recorded its maiden revenue in the 2021 financial year.

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

All upfront payments from outbound partnering transactions in the first quarter have been received by Kazia.

SYDNEY, July 21, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a leading drug development company in the field of brain cancer, today recognizes Glioblastoma (GBM) Awareness Day and calls for a greater focus on re...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

The fortunes of ASX healthcare shares can often swing on one momentous milestone. Examples of such a make-or-break event could be a breakthrough invention, successful product trial, or regulatory approval (or rejection). Such incidents can...

SYDNEY, June 30, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update on recent progress with its two pipeline assets, paxalisib and EVT801...

The GBM AGILE pivotal study of paxalisib is recruiting ahead of expectations, with almost 25 sites now open to the paxalisib arm in the US across several prestigious centres.

Summary Afterpay jumps on plans to expand reach with U.S. merchants Althea enters South African cannabis market worth US$667 million Bluechiip shares close strong on a settlement agreement with Labcon North America The S&P/ASX...

Summary The ASX 200 closed lower for the second day in a row, falling 0.32% to 7,275.30. The ASX health care and energy stocks were among top losers, while tech and consumer staples emerged as top gainers. Australian retailer Woolwort...

A Kazia-licensed oncology drug has secured manufacturing patents in two key countries, providing an additional layer of protection for the treatment candidate over the next 15 years.

Oncology-focused drug development company Kazia Therapeutics (ASX:KZA) has announced the grant of patents by the respective agencies of the US and India for the manufacturing process for paxalisib.

Recent advances in our still-shallow understanding of the human brain have led to a renewed interest in companies that focus on neuroscience. The most famous neuroscience startup, Elon Musk’s Neuralink, is probably the first company that co...

SYDNEY, June 15, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it has entered a collaboration with the Joan & Sanford I Weill Medica...

Shares in Kazia Therapeutics Ltd (ASX: KZA) lifted today after news its investigational drug Paxalisib will be part of another study for the treatment of brain cancer. At market close, the Kazia share price is $1.40 – 6.87% higher than its...

A new study will evaluate the efficacy of Kazia’s paxalisib candidate in patients with newly diagnosed or recurrent glioblastoma when combined with a ketogenic diet and metformin.

ShareCafeAlzheimer’s Decision Sends Positive Message to Aussie Biotechs The US Food and Drug Administration’s landmark but controversial approval of a new treatment for Alzheimer’s disease suggests a sea change in the regulator’s attitude t...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

SYDNEY, June 7, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia’s investigational new drug, paxalisib, in primar...

The Kazia Therapeutics Ltd (ASX: KZA) share price is edging lower, down 2% in morning trade. Below we take a look at the oncology-focused drug development company’s latest clinical trial update. What update did Kazia provide? Kazia Therape...

The DFCI study (NCT04906096) is an open-label phase II clinical trial of paxalisib in PCNSL and is expected to recruit up to 25 patients and up to two years to complete.

During the March quarter, the oncology-focused drug development company saw maiden revenue of A$5.3 million and its cash position increased to A$19.7 million end-March.